ICUI vs BDX vs BSX vs HSIC

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus -6. 4% for ICU Medical, Inc. (ICUI). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate ICU Medical, Inc. (ICUI) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 6x versus ICU Medical, Inc. at 4186. 1x. On forward P/E, Becton, Dickinson and Company is actually cheaper at 12. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 74x versus Henry Schein, Inc. 's 4. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -38. 4% for ICU Medical, Inc. (ICUI). Over 10 years, the gap is even starker: BSX returned +155. 5% versus HSIC's +5. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus ICU Medical, Inc. 's 1. 23β — meaning ICUI is approximately 258% more volatile than BSX relative to the S&P 500. On balance sheet safety, Boston Scientific Corporation (BSX) carries a lower debt/equity ratio of 51% versus 77% for Henry Schein, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus -6. 4% for ICU Medical, Inc. (ICUI). On earnings-per-share growth, the picture is similar: ICU Medical, Inc. grew EPS 100. 6% year-over-year, compared to -0. 5% for Becton, Dickinson and Company. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Boston Scientific Corporation (BSX) is the more profitable company, earning 14.

4% net margin versus 0. 0% for ICU Medical, Inc. — meaning it keeps 14. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus 4. 8% for ICUI. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 74x versus Henry Schein, Inc. 's 4. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Becton, Dickinson and Company (BDX) trades at 12. 3x forward P/E versus 16. 7x for Boston Scientific Corporation — 4. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 61. 4% to $91. 33.

In this comparison, BDX (2.

7% yield) pays a dividend. ICUI, BSX, HSIC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 7% yield). Both have compounded well over 10 years (BDX: +80. 2%, ICUI: +19. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ICUI is a small-cap quality compounder stock; BDX is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock; HSIC is a small-cap quality compounder stock. BDX pays a dividend while ICUI, BSX, HSIC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.